Connect to other sites within the UBM Medica Network
Primary Metastatic Small Intestinal Carcinoid Tumor Without Carcinoid Syndrome
Small intestinal “carcinoid” or well-differentiated grade 1 neuroendocrine tumors can have an insidious onset or be diagnosed serendipitously at the time of surgery, during the workup for another disorder, or during a screening test.
RADIANT-4: Everolimus Effective in Lung, GI NETs
Nonfunctional neuroendocrine tumors of lung or gastrointestinal origin were safely and effectively treated with the mTOR inhibitor everolimus.
Lutathera Delayed Progression of Midgut Neuroendocrine Tumors
Patients with midgut neuroendocrine tumors had significantly delayed disease progression when treated with Lutathera compared with the current standard of care.
FDA Approves Lanreotide Injection for GEP-NETs
The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
Initial Treatment of Well-Differentiated Neuroendocrine Tumors
In patients with advanced, unresectable NETs, there are several treatment options; which of these may be considered depends on the site of origin of the tumor.
Neuroendocrine (Small-Cell) Carcinomas: Why They Teach Us Essential Lessons About Prostate Cancer
Aggressive variants of prostate cancer often take the form of neuroendocrine or small-cell carcinomas, which frequently lack androgen receptor expression and respond poorly to hormonal therapies.
Small-Cell/Neuroendocrine Prostate Cancer: A Growing Threat?
Treatment-emergent small-cell/neuroendocrine prostate cancer is likely to become of increasing clinical relevance in the era of widespread use of potent androgen receptor–targeted therapies.
By clicking Accept, you agree to become a member of the UBM Medica Community.